tailieunhanh - Báo cáo y học: "Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: "Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma. | Respiratory Research BioMed Central Research Open Access Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast a randomised controlled trial investigating the effects on airway inflammation in asthma Ian Pavord 1 Ashley Woodcock2 Debbie Parker1 Leanne Rice3 for the SOLTA study group Address 1Glenfield Hospital Leicester UK 2Wythenshawe Hospital Manchester UK and 3GlaxoSmithKline UK Uxbridge UK Email Ian Pavord - Ashley Woodcock - Debbie Parker - dp66@ Leanne Rice - Corresponding author Published 27 September 2007 Received 27 November 2006 Accepted 27 September 2007 Respiratory Research 2007 8 67 doi 1465-9921 -8-67 This article is available from http content 8 1 67 2007 Pavord et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids and little is known about the effects of different treatments on airway inflammation. In this double-blind placebo-controlled parallel group study we compared the effects of salmeterol plus fluticasone propionate FP Seretide SFC and FP plus montelukast FP M on sputum inflammatory markers airway responsiveness lung function and symptoms in adult asthmatics. Methods Sixty-six subjects were randomised to SFC or FP M for 12 weeks. The primary outcome was changes in neutrophil eosinophil macrophage lymphocyte and epithelial cell levels in induced sputum. Additional outcomes included the change in other sputum markers of airway inflammation airway responsiveness symptom control and lung function. Results